image credit- shutterstock
Taiwan-based Jyong Biotech, specialising in the treatment of urinary system diseases, with an initial focus on the markets of the US, the EU and Asia, has entered into a non-binding Memorandum of Understanding (MoU) with a Vietnam‑based pharmaceutical distribution company headquartered in Ho Chi Minh City, to evaluate the development and commercialisation of MCS‑2 in the Vietnam pharmaceutical market.
Under the terms of the MoU, Jyong Biotech and the Vietnam pharmaceutical distribution company will proceed with due diligence and discussions to determine the scope and structure of any definitive collaboration, including commercial strategy, regulatory pathway and local market execution.
Fu Feng Kuo, CEO and Chairwoman of Jyong Biotech, commented, “This MOU represents an important step in our Asia‑focused strategy to bring plant‑derived MCS therapies to new markets. Vietnam presents meaningful opportunities for patient access and local partnership, and we are committed to working closely with our prospective partner to evaluate viable regulatory and commercial pathways while safeguarding the scientific and clinical integrity of MCS‑2.”
As of present day, MCS-2 remains an investigational new drug candidate and has not been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on material developments.
